ATCC ATCC Logo 0

Immuno-oncology Research Tools

Advanced biological models to help you transform the cancer treatment landscape

Cancer Research

Support your cutting-edge research with 2-D and 3-D patient-derived cancer models

Harness the power of the immune system to fight cancer

Cancer immunotherapy has emerged as an exciting new approach for cancer treatment, and immuno-oncology is one of the fastest growing fields in oncology. As compared to traditional cancer therapies that act directly on cancerous tumors, immuno-oncology therapy offers a unique approach that uses the body’s immune system to selectively target and eradicate tumor cells. These therapies also provide long-lasting memory to the immune system, enabling it to continue fighting against cancer cells even after remission.

The development of immunomodulatory drugs and biologics dictates a clear need for human cell-based models to evaluate immune activation. To answer this need, ATCC provides a large collection of fully characterized and authenticated cell lines, human primary cells, and advanced cell models.

Check out our posters

Cell Models for Developing ADCC Assays

Our data demonstrate the utility of primary NK cells and luciferase reporter tumor cell lines in developing ADCC assays for immuno-oncology drug screening.

Watch the poster presentation

Checkpoint Molecule Profiling

In this study, we present a comprehensive checkpoint molecule profiling data set for T cells lines and tumor cell lines derived from various cancer types.

Watch the poster presentation

Explore our comprehensive data set for checkpoint molecule levels

Although immune checkpoint blockades have exhibited anti-tumor effects in multiple cancer types, there are still challenges to overcome such as resistance and low response rate. Thus, there is a need for comprehensive data on the expression levels of checkpoint molecules based on cancer type, which can be utilized to guide specific treatment plans and combinations.

ATCC has complied a comprehensive data set of checkpoint molecule expression levels on a variety of tumor and immune cell lines and primary T cells. The cells that were tested demonstrate high expression levels of both checkpoint inhibitory and co-stimulatory molecules. These established cell lines can be incorporated into simple blocking assays or be integrated into co-culture testing systems. Additionally, this information provides a relevant and accessible model system for studying checkpoint molecule interactions and screening biologics as cancer immunotherapy treatments.

Table 1: Checkpoint molecule expression levels of immune cell receptors

The expression levels of established and novel inhibitory check point molecule receptors were profiled on basal immune cell lines available at ATCC by FACS analysis. HLA typing is identified by low expression (-) and high expression (+). Conditional formatting is added to the table to compare the expression of checkpoint molecules between cell lines (compare within each column). The value is calculated by subtracting the median fluorescence intensity (MFI) of the sample by the MFI of the isotype control.

Table 2: Checkpoint molecule expression levels of immune cell receptors

The expression levels of established and novel co-stimulatory check point molecule receptors were profiled on basal immune cell lines available at ATCC by FACS analysis. HLA typing is identified by low expression (-) and high expression (+). Conditional formatting is added to the table to compare the expression of checkpoint molecules between cell lines (compare within each column). The value is calculated by subtracting the median fluorescence intensity (MFI) of the sample by the MFI of the isotype control.

Table 3: Checkpoint molecule expression levels of tumor cell ligands

The expression levels of established and novel checkpoint inhibitory molecule ligands were profiled on basal (-) and 100 ng/mL IFNγ-stimulated (+) tumor cell lines available at ATCC were profiled by FACS analysis. HLA typing is identified by low expression (-) and high expression (+). Conditional formatting is added to the table to compare the expression of checkpoint molecules between cell lines (compare within each column). The value is calculated by subtracting the median fluorescence intensity (MFI) of the sample by the MFI of the control isotype.

Table 4: Checkpoint molecule expression levels of tumor cell ligands.

The expression levels of established and novel co-stimulatory checkpoint molecule ligands were profiled on basal (-) and 100 ng/mL IFNγstimulated (+) tumor cell lines available at ATCC were profiled by FACS analysis. HLA typing is identified by low expression (-) and high expression (+). Conditional formatting is added to the table to compare the expression of checkpoint molecules between cell lines (compare within each column). The value is calculated by subtracting the median fluorescence intensity (MFI) of the sample by the MFI of the control isotype.

Watch our webinar to learn how THP-1 reporter cells can be used in immuno-oncology research